Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients
AUTOR(ES)
Burnatt, Graciele, Licínio, Marley Aparecida, Gaspar, Pâmela Cristina, Ferreira, Arthur Schveitzer, Reis, Manoela Lira, Moraes, Ana Carolina Rabello de, Sincero, Thaís Cristine Marques, Santos-Silva, Maria Cláudia
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
22/06/2017
RESUMO
ABSTRACT When the FLT3 gene is mutated, it originates a modified receptor with structural changes, which give survival advantage and malignant hematopoietic cell proliferation. Thus, the presence of mutations in this gene is considered an unfavorable prognostic factor. A total of 85 consecutive samples of newly diagnosed untreated patients with AL were included in the study after they provided their informed consent. FLT3 gene mutations were detected by PCR. For the pediatric group, a positive correlation was observed between WBC count and the presence of FLT3-ITD in patients with AML and ALL. Furthermore, children with AML who had the FLT3-ITD mutation showed a tendency to express CD34 in blast cells. In the adult group, the AML patients with FLT3-ITD who expressed CD34 in blast cells had a tendency to worse progression. The present data indicate no association between the prognostic factors evaluated and FLT3 gene mutations in adult with AL. Yet, the presence of FLT3-ITD mutation was significantly related with WBC count in the pediatric group. These findings demonstrate that FLT3 gene mutations can be considered as independent poor prognostic factors.
Documentos Relacionados
- Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3
- Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes
- Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival
- Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
- Pretreatment with Recombinant Flt3 Ligand Partially Protects against Progressive Cutaneous Leishmaniasis in Susceptible BALB/c Mice